Loading
A phase 3 trial of Rilvegostomig and Pembrolizumab in non-small-cell lung cancer, run by AstraZeneca, now recruiting.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT06868277 by AstraZeneca, with 830 participants planned, started 2025-04-10 and due to reach its primary completion in 2030-01-17. Interventions recorded: Rilvegostomig and Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Rilvegostomig, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Rilvegostomig, AstraZeneca, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares AstraZeneca, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Rilvegostomig, AstraZeneca, Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/